Randomized trial of same- versus opposite-arm coadministration of inactivated influenza and SARS-CoV-2 mRNA vaccines
Authors:
- Wen Shi LeeWLWen Shi Lee
- Kevin J. SelvaKSKevin J. Selva
- Jennifer AudsleyJAJennifer Audsley
- Helen E. KentHKHelen E. Kent
- Arnold ReynaldiARArnold Reynaldi
- Timothy E. SchlubTSTimothy E. Schlub
- Deborah CromerDCDeborah Cromer
- David S. KhouryDKDavid S. Khoury
- Heidi PeckHPHeidi Peck
- Malet AbanMAMalet Aban
- Mai Ngoc VuMVMai Ngoc Vu
Open Access
- 7 January 2025
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (4)
Abstract
BACKGROUND: The immunogenicity of current influenza vaccines needs improvement. Inactivated influenza and COVID-19 mRNA vaccines can be coadministered, but randomized controlled trial data are lacking on whether the 2 vaccines are more immunogenic if given in the same arm or opposite arms. Murine studies suggest mRNA vaccines can adjuvant influenza vaccines when coformulated and codelivered. METHODS: We randomly assigned 56 adults to receive the Afluria quadrivalent inactivated influenza and Moderna monovalent SARS-CoV-2 XBB.1.5 mRNA vaccines, either in opposite arms or both in the same arm at the same site. The primary endpoint was the difference in median combined serum hemagglutination inhibition titer to the H1, H3, and B-Vic vaccine influenza strains after vaccination. RESULTS: We found no significant difference in hemagglutination inhibition antibody levels between the groups ( P = 0.30), with the same-arm group having a 1.26-fold higher titer than the opposite-arm group. There were no differences in analyses of antibodies against individual influenza strains or in nasal or saliva antibody levels. While both binding and neutralizing antibody titers against SARS-CoV-2 were not significantly different between groups postvaccination, there was a higher fold-change in BA.5 and ancestral strain neutralizing antibodies in the opposite-arm group. CONCLUSION: Influenza vaccination is equivalently immunogenic if given in the same arm or opposite arms as the SARS-CoV-2 vaccine, but it may be preferable to administer the SARS-CoV-2 vaccine at a different site from influenza vaccines. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12624000445572. FUNDING: Australian National Health and Medical Research Council, Australian Medical Research Future Fund, and National Institutes of Health (UH2AI176172).Keywords
Funding Information
- National Health and Medical Research Council (2016491)
- Medical Research Future Fund, Australia (2016062)
This publication has 21 references indexed in Scilit:
- Multiple vaccine comparison in the same adults reveals vaccine-specific and age-related humoral response patterns: an open phase IV trialNature Communications, 2024
- Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responsesEBioMedicine, 2024
- Concomitant administration of seasonal influenza and COVID-19 mRNA vaccinesEmerging Microbes & Infections, 2024
- Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trialThe Lancet Regional Health - Europe, 2023
- Innate immune mechanisms of mRNA vaccinesImmunity, 2022
- Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responsesImmunity, 2021
- Clinical efficacy and safety of high dose trivalent influenza vaccine in adults and immunosuppressed populations – A systematic review and meta-analysisJournal of Infection, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Nasosorption as a Minimally Invasive Sampling Procedure: Mucosal Viral Load and Inflammation in Primary RSV BronchiolitisThe Journal of Infectious Diseases, 2017
- Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: A systematic review with meta-analyses of controlled trialsVaccine, 2012